Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Resource Library

Classification, Screening, and Diagnosis of PH


  Sign in to add a review

Leave a Comment

Conference: 2014 International PHA Conference and Scientific Sessions

Release Date: 03.27.2017


Murali Chakinala, M.D.
Washington University School of Medicine
St. Louis, Mo. 

Educational Objectives

To support the attainment of knowledge, competence, and performance, the learner should be able to achieve the following objectives:
  1. Review the latest classifications scheme for pulmonary hypertension
  2. Identify patient groups at increased risk for pulmonary arterial hypertension and the vital role of echocardiography
  3. Translate the non-invasive workup of PH patients into a pre-cath probability for PAH
  4. Emphasize the vital role of right heart catheterization in establishing a PAH diagnosis 

Intended Audience

This continuing education activity is intended for;
  1. Non-physician
  2. Nurses
  3. Other 
  4. Physicians

Resolution of Conflict of Interest

PESG has implemented a process to resolve the conflict of interests for each activity. In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, PESG has resolved the conflict by an external content review.

Unapproved/Off-Label Use Disclosure

PESG requires  faculty to disclose to the participants: 
  1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved) 
  2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labeling. This information is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Faculty, Planners, Staff Disclosure Information

All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity. The faculty and planners of this educational activity disclose the following:
  1. Murali Chakinala, M.D., is a consultant for Actelion Pharmaceuticals US, Inc.; Gilead Sciences, Inc.; United Therapeutics Corporation; Bayer HealthCare and Medtronic, Inc. He is on speaker bureaus for Gilead Sciences, Inc.; and United Therapeutics Corporation and receives research support from Actelion Pharmaceuticals US, Inc.; Gilead Sciences, Inc.; United Therapeutics Corporation; Bayer HealthCare; Novartis Pharmaceuticals; Ikaria, Inc.; Medtronic, Inc.; Aires; and Reata Pharameuticals, Inc. 
  2. PHA and PESG Staff have no relevant financial relationships to disclose.